Which has preferable earnings and valuation, BHVN or TGTX?

TG Therapeutics has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$5.67 N/A TG Therapeutics $616.29M 13.87 $447.18M $2.86 19.52

Is BHVN or TGTX more profitable?

TG Therapeutics has a net margin of 65.95% compared to Biohaven's net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -866.46% -137.99% TG Therapeutics 65.95% 88.73% 43.44%

Which has higher earnings & valuation, BHVN or ABVX?

Abivax is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$5.67 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is BHVN or ABVX more profitable?

Abivax's return on equity of -99.02% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -866.46% -137.99% Abivax N/A -99.02% -70.26%

Does the media favor BHVN or ABVX?

In the previous week, Biohaven had 1 more articles in the media than Abivax. MarketBeat recorded 4 mentions for Biohaven and 3 mentions for Abivax. Abivax's average media sentiment score of 0.84 beat Biohaven's score of 0.58 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BHVN or PRAX more profitable?

Praxis Precision Medicines' return on equity of -43.02% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -866.46% -137.99% Praxis Precision Medicines N/A -43.02% -40.22%

Does the media favor BHVN or PRAX?

In the previous week, Praxis Precision Medicines had 7 more articles in the media than Biohaven. MarketBeat recorded 11 mentions for Praxis Precision Medicines and 4 mentions for Biohaven. Praxis Precision Medicines' average media sentiment score of 0.63 beat Biohaven's score of 0.58 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, BHVN or IBRX?

ImmunityBio has higher revenue and earnings than Biohaven. ImmunityBio is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$5.67 N/A ImmunityBio $113.29M 80.52 -$351.40M -$0.85 N/A

Is BHVN or IBRX more profitable?

Biohaven has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -866.46% -137.99% ImmunityBio -606.15% N/A -59.53%

Does the media prefer BHVN or IBRX?

In the previous week, ImmunityBio had 1 more articles in the media than Biohaven. MarketBeat recorded 5 mentions for ImmunityBio and 4 mentions for Biohaven. Biohaven's average media sentiment score of 0.58 beat ImmunityBio's score of 0.33 indicating that Biohaven is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SYRE or BHVN more profitable?

Spyre Therapeutics' return on equity of -42.88% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -42.88% -27.76% Biohaven N/A -866.46% -137.99%

Does the media prefer SYRE or BHVN?

In the previous week, Spyre Therapeutics had 6 more articles in the media than Biohaven. MarketBeat recorded 10 mentions for Spyre Therapeutics and 4 mentions for Biohaven. Biohaven's average media sentiment score of 0.58 beat Spyre Therapeutics' score of 0.42 indicating that Biohaven is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biohaven 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Biohaven (BHVN) Competitors

$15.79 +0.45 (+2.94%)

Closing price 06/26/2026 03:59 PM Eastern

Extended Trading

$15.89 +0.10 (+0.65%)

As of 06/26/2026 07:46 PM Eastern

Compare

BHVN vs. TGTX, ABVX, PRAX, IBRX, and SYRE

Should you buy Biohaven stock or one of its competitors? MarketBeat compares Biohaven with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biohaven include TG Therapeutics (TGTX), Abivax (ABVX), Praxis Precision Medicines (PRAX), ImmunityBio (IBRX), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Biohaven compare to TG Therapeutics?

Biohaven (NYSE:BHVN) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Biohaven has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market.

88.8% of Biohaven shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 13.8% of Biohaven shares are held by insiders. Comparatively, 8.9% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Biohaven had 3 more articles in the media than TG Therapeutics. MarketBeat recorded 4 mentions for Biohaven and 1 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 1.87 beat Biohaven's score of 0.58 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Biohaven	Positive
TG Therapeutics	Very Positive

Biohaven presently has a consensus price target of $22.27, suggesting a potential upside of 41.01%. TG Therapeutics has a consensus price target of $58.60, suggesting a potential upside of 4.96%. Given Biohaven's higher possible upside, analysts clearly believe Biohaven is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	1 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.72
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

TG Therapeutics has a net margin of 65.95% compared to Biohaven's net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
TG Therapeutics	65.95%	88.73%	43.44%

TG Therapeutics has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
TG Therapeutics	$616.29M	13.87	$447.18M	$2.86	19.52

Summary

TG Therapeutics beats Biohaven on 9 of the 15 factors compared between the two stocks.

How does Biohaven compare to Abivax?

Biohaven (NYSE:BHVN) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Biohaven has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, Abivax has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

Abivax's return on equity of -99.02% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
Abivax	N/A	-99.02%	-70.26%

Biohaven currently has a consensus target price of $22.27, suggesting a potential upside of 41.01%. Abivax has a consensus target price of $130.08, suggesting a potential upside of 33.41%. Given Biohaven's higher possible upside, equities analysts clearly believe Biohaven is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	1 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.72
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Abivax is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 13.8% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Biohaven had 1 more articles in the media than Abivax. MarketBeat recorded 4 mentions for Biohaven and 3 mentions for Abivax. Abivax's average media sentiment score of 0.84 beat Biohaven's score of 0.58 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Abivax beats Biohaven on 7 of the 13 factors compared between the two stocks.

How does Biohaven compare to Praxis Precision Medicines?

Biohaven (NYSE:BHVN) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Praxis Precision Medicines has higher revenue and earnings than Biohaven. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
Praxis Precision Medicines	$8.55M	1,068.86	-$303.27M	-$13.37	N/A

In the previous week, Praxis Precision Medicines had 7 more articles in the media than Biohaven. MarketBeat recorded 11 mentions for Praxis Precision Medicines and 4 mentions for Biohaven. Praxis Precision Medicines' average media sentiment score of 0.63 beat Biohaven's score of 0.58 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Biohaven currently has a consensus price target of $22.27, suggesting a potential upside of 41.01%. Praxis Precision Medicines has a consensus price target of $566.21, suggesting a potential upside of 72.74%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Praxis Precision Medicines is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	1 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.72
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95

Biohaven has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, indicating that its share price is 171% more volatile than the broader market.

88.8% of Biohaven shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 13.8% of Biohaven shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Praxis Precision Medicines' return on equity of -43.02% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Summary

Praxis Precision Medicines beats Biohaven on 11 of the 14 factors compared between the two stocks.

How does Biohaven compare to ImmunityBio?

Biohaven (NYSE:BHVN) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Biohaven has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
ImmunityBio	-606.15%	N/A	-59.53%

In the previous week, ImmunityBio had 1 more articles in the media than Biohaven. MarketBeat recorded 5 mentions for ImmunityBio and 4 mentions for Biohaven. Biohaven's average media sentiment score of 0.58 beat ImmunityBio's score of 0.33 indicating that Biohaven is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ImmunityBio has higher revenue and earnings than Biohaven. ImmunityBio is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
ImmunityBio	$113.29M	80.52	-$351.40M	-$0.85	N/A

Biohaven presently has a consensus price target of $22.27, suggesting a potential upside of 41.01%. ImmunityBio has a consensus price target of $14.20, suggesting a potential upside of 63.03%. Given ImmunityBio's higher probable upside, analysts clearly believe ImmunityBio is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	1 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.72
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

88.8% of Biohaven shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 13.8% of Biohaven shares are held by insiders. Comparatively, 66.1% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Biohaven has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, indicating that its share price is 97% less volatile than the broader market.

Summary

ImmunityBio beats Biohaven on 8 of the 15 factors compared between the two stocks.

How does Biohaven compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Biohaven (NYSE:BHVN) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Spyre Therapeutics has higher revenue and earnings than Biohaven. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,575.69	-$155.20M	-$2.08	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

In the previous week, Spyre Therapeutics had 6 more articles in the media than Biohaven. MarketBeat recorded 10 mentions for Spyre Therapeutics and 4 mentions for Biohaven. Biohaven's average media sentiment score of 0.58 beat Spyre Therapeutics' score of 0.42 indicating that Biohaven is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biohaven	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics' return on equity of -42.88% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Biohaven	N/A	-866.46%	-137.99%

Spyre Therapeutics currently has a consensus target price of $95.83, indicating a potential upside of 9.04%. Biohaven has a consensus target price of $22.27, indicating a potential upside of 41.01%. Given Biohaven's higher possible upside, analysts plainly believe Biohaven is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Biohaven	1 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.72

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 13.8% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Spyre Therapeutics has a beta of 3.05, indicating that its stock price is 205% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

Summary

Spyre Therapeutics beats Biohaven on 9 of the 12 factors compared between the two stocks.

Get Biohaven News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHVN vs. The Competition

Export

Metric	Biohaven	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$2.38B	$3.63B	$7.04B	$23.31B
Dividend Yield	N/A	2.23%	2.66%	4.07%
P/E Ratio	N/A	21.75	25.90	31.64
Price / Sales	N/A	333.81	600.60	21.38
Price / Cash	N/A	141.14	47.95	24.80
Price / Book	40.49	8.33	10.78	4.74
Net Income	-$738.82M	$23.91M	$3.58B	$1.07B
7 Day Performance	16.43%	3.42%	2.22%	0.99%
1 Month Performance	54.51%	0.39%	-0.09%	0.46%
1 Year Performance	11.98%	65.22%	34.39%	25.30%

Biohaven Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHVN Biohaven	2.9634 of 5 stars	$15.79 +2.9%	$22.27 +41.0%	+12.0%	$2.38B	N/A	N/A	239	Analyst Forecast Gap Up High Trading Volume
TGTX TG Therapeutics	2.9133 of 5 stars	$54.40 +2.2%	$58.60 +7.7%	+52.0%	$8.15B	$616.29M	19.02	290	Positive News
ABVX Abivax	2.9324 of 5 stars	$101.66 +2.5%	$130.08 +28.0%	+1,217.6%	$7.91B	N/A	N/A	61
PRAX Praxis Precision Medicines	3.5409 of 5 stars	$303.39 +7.5%	$566.21 +86.6%	+662.3%	$7.87B	$8.55M	N/A	110	Insider Trade Gap Up
IBRX ImmunityBio	2.4762 of 5 stars	$7.22 -1.9%	$14.20 +96.7%	+222.6%	$7.71B	$113.29M	N/A	590	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BHVN) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biohaven (BHVN) Competitors

BHVN vs. TGTX, ABVX, PRAX, IBRX, and SYRE

How does Biohaven compare to TG Therapeutics?

Summary

How does Biohaven compare to Abivax?

Summary

How does Biohaven compare to Praxis Precision Medicines?

Summary

How does Biohaven compare to ImmunityBio?

Summary

How does Biohaven compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN vs. The Competition

Biohaven Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biohaven (BHVN) Competitors

BHVN vs. TGTX, ABVX, PRAX, IBRX, and SYRE

How does Biohaven compare to TG Therapeutics?

Which has more risk & volatility, BHVN or TGTX?

Do institutionals & insiders have more ownership in BHVN or TGTX?

Does the media favor BHVN or TGTX?

Do analysts recommend BHVN or TGTX?

Is BHVN or TGTX more profitable?

Which has preferable earnings and valuation, BHVN or TGTX?

Summary

How does Biohaven compare to Abivax?

Which has more risk & volatility, BHVN or ABVX?

Is BHVN or ABVX more profitable?

Do analysts prefer BHVN or ABVX?

Which has higher earnings & valuation, BHVN or ABVX?

Do institutionals and insiders hold more shares of BHVN or ABVX?

Does the media favor BHVN or ABVX?

Summary

How does Biohaven compare to Praxis Precision Medicines?

Which has preferable valuation and earnings, BHVN or PRAX?

Does the media favor BHVN or PRAX?

Do analysts rate BHVN or PRAX?

Which has more volatility & risk, BHVN or PRAX?

Do insiders and institutionals hold more shares of BHVN or PRAX?

Is BHVN or PRAX more profitable?

Summary

How does Biohaven compare to ImmunityBio?

Is BHVN or IBRX more profitable?

Does the media prefer BHVN or IBRX?

Which has better earnings and valuation, BHVN or IBRX?

Do analysts rate BHVN or IBRX?

Do institutionals & insiders believe in BHVN or IBRX?

Which has more risk and volatility, BHVN or IBRX?

Summary

How does Biohaven compare to Spyre Therapeutics?

Which has preferable valuation and earnings, SYRE or BHVN?

Does the media prefer SYRE or BHVN?

Is SYRE or BHVN more profitable?

Do analysts recommend SYRE or BHVN?

Do institutionals and insiders have more ownership in SYRE or BHVN?

Which has more volatility and risk, SYRE or BHVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN vs. The Competition

Biohaven Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools